Corrigendum to “Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study” [Eur J Cancer 213 (December) (2024) 115078] - Azad, Arun; Fizazi, Karim; Matsubara, Nobuaki; Saad, Fred; De Giorgi, Ugo; Joung, Jae Young; Fong, Peter C. C.; Jones, Robert J.; Zschäbitz, Stefanie; Oldenburg, Jan; Shore, Neal D.; Dunshee, Curtis; et al. (European journal of cancer, 2026)
Online verfügbar: 13. November 2025, Artikelversion: 18. November 2025